GlassScriptPhysician profile
Yaoli Yang
NPI 1982090122
$3,627.30
in general payments reported to CMS, 2019-2025
25 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.83 · 2022: $588 · 2023: $734 · 2024: $850 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402 · Travel and Lodging: $474 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.90 |
| Travel and Lodging | $474.38 |
| Education | $137.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $474.38 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $414.01 | 2022-2025 | Dupixent |
| Insmed, INC. | $364.44 | 2022-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $331.58 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $277.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.93 | 2022-2025 | Ofev, Stiolto Respimat |
| Philips North America LLC | $214.15 | 2022-2024 | (8874) Incourage |
| Glaxosmithkline, LLC. | $202.80 | 2022-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $139.80 | 2022-2025 | Dalvance, Teflaro |
| Verona Pharma, INC. | $119.05 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $100.65 | 2022-2025 | Zerbaxa, Winrevair, Recarbrio |
| Gilead Sciences, INC. | $95.36 | 2022-2023 | Veklury |
| Pulmonx Corporation | $73.64 | 2022-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| United Therapeutics Corporation | $67.32 | 2022-2025 | Tyvaso |
| Grifols USA, LLC | $65.79 | 2023-2024 | Prolastin-C Liquid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $62.91 | 2022 | |
| Baxter Healthcare | $62.63 | 2024-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Volara System |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.33 | 2022-2023 | |
| Electromed, INC. | $49.77 | 2024-2025 | Smartvest |
| Medtronic, INC. | $28.73 | 2024 | Illumisite |
| Inspire Medical Systems, INC. | $26.16 | 2024 | Inspire |
| Mylan Specialty L.P. | $25.83 | 2021 | |
| Lilly USA, LLC | $23.72 | 2025 | Zepbound, Mounjaro |
| Genentech USA, INC. | $21.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaoli Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.